-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 177Lu-Satoreotide in Paraganglioma (Glomus Jugulare Tumor)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 177Lu-Satoreotide in Paraganglioma (Glomus Jugulare Tumor) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 177Lu-Satoreotide in Paraganglioma (Glomus Jugulare Tumor) Drug Details: 177Lu-satoreotide (OPS-201,...
-
Product Insights
Small-Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Small cell lung cancer (SCLC) is the most aggressive form of lung cancer. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. The Small-Cell Lung Cancer market research report provides comprehensive information on the therapeutics under development for SCLC, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its...